Axsome: Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint.Symbravo demonstrated statistically significantly greater migraine treatment response than oral CGRP inhibitors, as measured by the Migraine Treatment Optimization Questionnaire (mTOQ-4) (5.2 versus 2.8, p0.001).Also Read: Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says AnalystIn the trial, Symbravo rapidly and substantially improved migraine pain and ...Full story available on Benzinga.com